Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ACRV with free AI briefings, catalyst countdowns, and dilution alerts.

ACRV · Acrivon Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90M Cash on Hand

15.2mo Cash Runway

20% Short Interest

$11.5 Analyst Target (6)

Follow ACRV by email Get an email when ACRV pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACRV, unsubscribe in one click. Privacy

📣 What ACRV Says Is Next

second quarter of 2027 · “Initiate additional internal programs utilizing AP3 platform in 2H 2026 As of December 31, 2025, the company had preliminary, unaudited cash, cash equivalents and investments of approximately $119 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.”
Company press release, Jan 8, 2026 · SEC filing
fourth quarter of 2026 · “IND submission anticipated in the fourth quarter of 2026 Anticipated Upcoming Milestones”
Company press release, Jan 8, 2026 · SEC filing
fourth quarter of 2026 · ““Finally, we continue to demonstrate the value of our AP3 platform with the nomination from our cell cycle program of ACR-6840, a potential first-in-class CDK11 inhibitor development candidate, with IND submission expected in the fourth quarter of 2026.”
Company press release, Jan 8, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

May 2027 · Phase 2 · Recruiting · A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Registry primary completion date, not a results date
Aug 2027 · Phase 1/2 · Recruiting · Study of ACR-2316 in Specific Advanced Solid Tumors
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Wee1/PKMYT1 Inhibitor ACR-2316	Specific Advanced Solid Tumors	Phase 1/2 · NCT06667141	Recruiting
Prexasertib (ACR-368)	Head and Neck Squamous Cell Carcinoma	Phase 2 · NCT06597565	Recruiting

Also used in these trials (approved or third-party drugs, not ACRV's own candidates): Gemcitabine Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACRV holds $90M in cash and short-term investments (as of Jun 30, 2026) and burns about $17.7M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 57 · Elevated

Cash runway 15 months +18
ATM program on file since Dec 2023 +15
Shelf registration (S-3, Dec 2023) +10
Share count +36% in a year +14

Recent financing filings on SEC EDGAR:

Apr 9, 2024 · Private placement (8-K Item 3.02) · 8-K
Dec 1, 2023 · Shelf registration with ATM program, up to $100M · S-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACRV files for a raise →

👥 Who Owns ACRV

Insiders 8.2% Other 5%+ holders 5.3% Institutions (56 holders) 50.3% Public and other holders 36.2%

Holder	Type	Shares	% of shares	As of
Peter Blume-Jensen President and CEO, Director	Insider	2,615,911	6.10%	2026-08-25
Sands Capital Life Sciences Pulse Fund I	5%+ holder (13G)	2,289,271	5.34%	2026-06-30
Sands Capital Alternatives, LLC	Institution (13F)	2,122,605	4.95%	2025-12-31
Kenneth Griffin	Institution (13G, 5%+)	1,721,867	4.02%	2025-11-14
Citadel Advisors Llc	Institution (13F)	1,641,884	3.83%	2025-12-31
Wellington Management Group, LLP	Institution (13F)	888,130	2.07%	2025-12-31
Vanguard Group Inc	Institution (13F)	698,857	1.63%	2025-12-31
Renaissance Technologies, LLC	Institution (13F)	634,169	1.48%	2025-12-31
Two Sigma Investments, LP	Institution (13F)	585,069	1.37%	2025-12-31
Acadian Asset Management. LLC	Institution (13F)	581,208	1.36%	2025-12-31
Marshall Wace LLP	Institution (13F)	496,081	1.16%	2025-12-31
RA CAPITAL MANAGEMENT, L.P. Director, 10% owner · +20,275 options	Insider	426,302	0.99%	2026-05-18

Share count 42,853,362 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-08-31 filed 2026-09-02	Levin Michaela	Award (A)	30,000	–	30,000
2026-08-31 filed 2026-09-02	Levin Michaela	Option award (A)	130,000	–	–
2026-08-25 filed 2026-08-27	Blume-Jensen Peter	Sale (S)	14,036	$2.21	2,230,052
2026-08-18 filed 2026-08-20	Peterson Katharine	Sale (S)	101	$2.01	18,033
2026-08-18 filed 2026-08-20	Miller Mary	Sale (S)	185	$2.01	82,009

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ACRV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACRV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z